Tocagen (TOCA) Now Covered by Leerink Swann

Investment analysts at Leerink Swann began coverage on shares of Tocagen (NASDAQ:TOCA) in a note issued to investors on Monday, April 15th, The Fly reports. The brokerage set a “market perform” rating and a $10.26 price target on the stock. Leerink Swann’s price objective points to a potential upside of 2.29% from the company’s previous close.

A number of other equities analysts also recently issued reports on TOCA. Zacks Investment Research downgraded Tocagen from a “buy” rating to a “hold” rating in a research report on Thursday, February 21st. B. Riley assumed coverage on Tocagen in a research report on Monday, December 31st. They set a “buy” rating and a $22.00 price target on the stock. Finally, Robert W. Baird assumed coverage on Tocagen in a research report on Friday, January 18th. They set an “outperform” rating and a $20.00 price target on the stock. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $19.48.

Tocagen stock traded down $0.57 during mid-day trading on Monday, reaching $10.03. 112,526 shares of the company were exchanged, compared to its average volume of 176,451. The company has a quick ratio of 5.91, a current ratio of 5.91 and a debt-to-equity ratio of 0.45. The firm has a market cap of $234.57 million, a P/E ratio of -4.11 and a beta of 3.29. Tocagen has a 12-month low of $6.47 and a 12-month high of $15.80.

Tocagen (NASDAQ:TOCA) last posted its earnings results on Tuesday, May 7th. The company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.01. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $2.01 million. Tocagen had a negative return on equity of 92.56% and a negative net margin of 271.43%. Equities analysts expect that Tocagen will post -3.07 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Requisite Energy Fund I LP acquired a new position in shares of Tocagen in the 4th quarter valued at $403,000. Vanguard Group Inc. increased its position in shares of Tocagen by 14.9% in the 3rd quarter. Vanguard Group Inc. now owns 787,550 shares of the company’s stock valued at $12,278,000 after acquiring an additional 101,874 shares during the period. BlackRock Inc. increased its position in shares of Tocagen by 25.2% in the 3rd quarter. BlackRock Inc. now owns 1,413,285 shares of the company’s stock valued at $22,033,000 after acquiring an additional 284,518 shares during the period. Caption Management LLC acquired a new position in shares of Tocagen in the 4th quarter valued at $98,000. Finally, Hound Partners LLC acquired a new position in shares of Tocagen in the 4th quarter valued at $871,000. 36.22% of the stock is currently owned by hedge funds and other institutional investors.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Recommended Story: Resistance Level

The Fly

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.